Mortality in Patients With Hypovolemic Shock Treated With Colloids or Crystalloids

• Autores: Christian Brun-Buisson, Junfeng Sun, Charles Natanson
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 311, Nº. 10, 2014, págs. 1069-1069
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Dr Annane and colleagues1 reported that 28-day mortality (primary end point) did not significantly differ between patients with hypovolemic shock assigned to various colloid fluid therapies (69% of whom received hydroxyethyl starch) vs crystalloid fluid therapies. They also reported that 90-day mortality (one of many secondary end points) was significantly higher with crystalloids.